Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/10429
Title: | Urine metabolome profiling of immune-mediated inflammatory diseases. |
Authors: | Alonso, Arnald Julià, Antonio Vinaixa, Maria Domènech, Eugeni Fernández-Nebro, Antonio Cañete, Juan D Ferrándiz, Carlos Tornero, Jesús Gisbert, Javier P Nos, Pilar Casbas, Ana Gutiérrez Puig, Lluís González-Álvaro, Isidoro Pinto-Tasende, José A Blanco, Ricardo Rodríguez, Miguel A Beltran, Antoni Correig, Xavier Marsal, Sara IMID Consortium |
Keywords: | Autoimmune diseases;Disease activity;Inflammatory diseases;Metabolomics;Urine biomarkers |
metadata.dc.subject.mesh: | Arthritis, Rheumatoid Autoimmune Diseases Biomarkers Case-Control Studies Colitis, Ulcerative Crohn Disease Humans Inflammation Lupus Erythematosus, Systemic Magnetic Resonance Spectroscopy Metabolome Metabolomics Psoriasis |
Issue Date: | 8-Sep-2016 |
Abstract: | Immune-mediated inflammatory diseases (IMIDs) are a group of complex and prevalent diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis. Using nuclear magnetic resonance, we analyzed the urine metabolome in a discovery cohort of 1210 patients and 100 controls. Within each IMID, two patient subgroups were recruited representing extreme disease activity (very high vs. very low). Metabolite association analysis with disease diagnosis and disease activity was performed using multivariate linear regression in order to control for the effects of clinical, epidemiological, or technical variability. After multiple test correction, the most significant metabolite biomarkers were validated in an independent cohort of 1200 patients and 200 controls. In the discovery cohort, we identified 28 significant associations between urine metabolite levels and disease diagnosis and three significant metabolite associations with disease activity (P FDR This study shows that urine is a source of biomarkers of clinical utility in IMIDs. We have found that IMIDs show similar metabolic changes, particularly between clinically similar diseases and we have found, for the first time, the presence of hub metabolites. These findings represent an important step in the development of more efficient and less invasive diagnostic and disease monitoring methods in IMIDs. |
URI: | http://hdl.handle.net/10668/10429 |
metadata.dc.identifier.doi: | 10.1186/s12916-016-0681-8 |
Appears in Collections: | Producción 2020 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
PMC5016926.pdf | 1,27 MB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License